What is HC Wainwright’s Estimate for ACTU Q1 Earnings?

Actuate Therapeutics (NASDAQ:ACTU) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Actuate Therapeutics in a report issued on Monday, March 17th. HC Wainwright analyst S. Ramakanth forecasts that the company will earn ($0.26) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. HC Wainwright also issued estimates for Actuate Therapeutics’ Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.79) EPS and FY2026 earnings at ($0.98) EPS.

Actuate Therapeutics Price Performance

Shares of Actuate Therapeutics stock opened at $7.46 on Wednesday. The firm has a 50 day simple moving average of $8.15 and a 200 day simple moving average of $8.07. Actuate Therapeutics has a fifty-two week low of $5.51 and a fifty-two week high of $11.73.

Institutional Trading of Actuate Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. BIOS Capital Management LP bought a new position in shares of Actuate Therapeutics during the fourth quarter worth $78,753,000. Voss Capital LP acquired a new stake in Actuate Therapeutics during the 4th quarter worth $440,000. Northwestern University bought a new position in Actuate Therapeutics during the third quarter worth about $207,000. Mercer Global Advisors Inc. ADV acquired a new position in Actuate Therapeutics in the fourth quarter valued at about $130,000. Finally, Sigma Planning Corp acquired a new position in Actuate Therapeutics in the fourth quarter valued at about $128,000.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.